JP2003511347A - III型内皮細胞一酸化窒素合成酵素のHMG−CoA還元酵素阻害物質による上方制御 - Google Patents
III型内皮細胞一酸化窒素合成酵素のHMG−CoA還元酵素阻害物質による上方制御Info
- Publication number
- JP2003511347A JP2003511347A JP2000606302A JP2000606302A JP2003511347A JP 2003511347 A JP2003511347 A JP 2003511347A JP 2000606302 A JP2000606302 A JP 2000606302A JP 2000606302 A JP2000606302 A JP 2000606302A JP 2003511347 A JP2003511347 A JP 2003511347A
- Authority
- JP
- Japan
- Prior art keywords
- nitric oxide
- endothelial cell
- oxide synthase
- subject
- cell nitric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27344599A | 1999-03-19 | 1999-03-19 | |
US09/273,445 | 1999-03-19 | ||
PCT/US2000/007221 WO2000056403A1 (fr) | 1999-03-19 | 2000-03-17 | Regulation positive de l'oxyde nitrique synthase des cellules endotheliales de type iii par des inhibiteurs de la hmg-coa reductase |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2003511347A true JP2003511347A (ja) | 2003-03-25 |
Family
ID=23043964
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000606302A Pending JP2003511347A (ja) | 1999-03-19 | 2000-03-17 | III型内皮細胞一酸化窒素合成酵素のHMG−CoA還元酵素阻害物質による上方制御 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1175246A4 (fr) |
JP (1) | JP2003511347A (fr) |
AU (1) | AU3760300A (fr) |
CA (1) | CA2368187A1 (fr) |
WO (1) | WO2000056403A1 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006033287A1 (fr) * | 2004-09-21 | 2006-03-30 | Sankyo Company, Limited | PRÉPARATION PHARMACEUTIQUE CONTENANT UN INHIBITEUR DE LA HMG-CoA RÉDUCTASE ET DE LA GLUTATHIONE |
JP2006117645A (ja) * | 2004-09-21 | 2006-05-11 | Sankyo Co Ltd | HMG−CoAリダクターゼ阻害剤とグルタチオンを含有する医薬組成物 |
JP2009513509A (ja) * | 2003-07-07 | 2009-04-02 | ビトップ アクツィエンゲゼルシャフト フュール ビオテヒニシェ オプティミールング | 肺疾患および心臓血管疾患の予防および治療用の吸入薬の製造のための極限環境細菌から得られたオスモライトの使用、ならびに活性薬剤成分としてオスモライトを含む吸入装置 |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6425881B1 (en) | 1994-10-05 | 2002-07-30 | Nitrosystems, Inc. | Therapeutic mixture useful in inhibiting lesion formation after vascular injury |
US6239172B1 (en) | 1997-04-10 | 2001-05-29 | Nitrosystems, Inc. | Formulations for treating disease and methods of using same |
US5968983A (en) | 1994-10-05 | 1999-10-19 | Nitrosystems, Inc | Method and formulation for treating vascular disease |
EP1175210A4 (fr) | 1999-03-19 | 2003-07-09 | Enos Pharmaceuticals Inc | Renforcement de la biodisponibilite des medicaments dans le cerveau |
US8168616B1 (en) * | 2000-11-17 | 2012-05-01 | Novartis Ag | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
US20020173535A1 (en) * | 2001-02-07 | 2002-11-21 | Renshaw Perry F. | Cholesterol-lowering agents as treatment for psychological and cognitive disorders |
DE10257360A1 (de) * | 2002-12-09 | 2004-07-08 | Fresenius Kabi Deutschland Gmbh | Gastro-intestinal verabreichbare Formulierung und deren Verwendung |
ES2421520T3 (es) * | 2003-04-28 | 2013-09-03 | Daiichi Sankyo Co Ltd | Potenciador de la producción de adiponectina |
CA2524175C (fr) | 2003-04-28 | 2016-06-14 | Sankyo Company Limited | Composition activant l'aptitude a consommer du sucre |
CA2545584C (fr) | 2003-11-17 | 2012-10-23 | Biomarin Pharmaceutical Inc. | Methodes et compositions destinees au traitement de troubles metaboliques |
US20080312189A1 (en) * | 2004-03-05 | 2008-12-18 | Eisai Co., Ltd. | Cadasil Treatment with Cholinesterase Inhibitors |
EP1951253A2 (fr) | 2005-10-26 | 2008-08-06 | Cotherix, Inc. | Fasudil en polytherapies pour traiter l'hypertension arterielle pulmonaire |
WO2008036846A2 (fr) * | 2006-09-22 | 2008-03-27 | Braincells, Inc. | Modulation induite par hmg-coa-réductase de la neurogenèse |
WO2009000592A1 (fr) * | 2007-06-25 | 2008-12-31 | Nicox S.A. | Utilisation de statines a liberation d'oxyde nitrique dans le traitement de l'hypertension arterielle pulmonaire |
US9216178B2 (en) | 2011-11-02 | 2015-12-22 | Biomarin Pharmaceutical Inc. | Dry blend formulation of tetrahydrobiopterin |
US20200253976A1 (en) * | 2017-09-28 | 2020-08-13 | University Of Massachusetts | Endothelial Facilitation in Neurodegerative Diseases by Cerebral Blood Flow Enhancement |
GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
EP3955936A1 (fr) | 2019-04-17 | 2022-02-23 | COMPASS Pathfinder Limited | Traitement de la dépression et de divers autres troubles au moyen de psilocybine |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444784A (en) * | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
US6369103B1 (en) * | 1994-01-18 | 2002-04-09 | Bristol-Myers Squibb Company | Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor |
US6147109A (en) * | 1997-10-14 | 2000-11-14 | The General Hospital Corporation | Upregulation of Type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors |
-
2000
- 2000-03-17 CA CA002368187A patent/CA2368187A1/fr not_active Abandoned
- 2000-03-17 WO PCT/US2000/007221 patent/WO2000056403A1/fr not_active Application Discontinuation
- 2000-03-17 EP EP00916511A patent/EP1175246A4/fr not_active Withdrawn
- 2000-03-17 AU AU37603/00A patent/AU3760300A/en not_active Abandoned
- 2000-03-17 JP JP2000606302A patent/JP2003511347A/ja active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009513509A (ja) * | 2003-07-07 | 2009-04-02 | ビトップ アクツィエンゲゼルシャフト フュール ビオテヒニシェ オプティミールング | 肺疾患および心臓血管疾患の予防および治療用の吸入薬の製造のための極限環境細菌から得られたオスモライトの使用、ならびに活性薬剤成分としてオスモライトを含む吸入装置 |
WO2006033287A1 (fr) * | 2004-09-21 | 2006-03-30 | Sankyo Company, Limited | PRÉPARATION PHARMACEUTIQUE CONTENANT UN INHIBITEUR DE LA HMG-CoA RÉDUCTASE ET DE LA GLUTATHIONE |
JP2006117645A (ja) * | 2004-09-21 | 2006-05-11 | Sankyo Co Ltd | HMG−CoAリダクターゼ阻害剤とグルタチオンを含有する医薬組成物 |
Also Published As
Publication number | Publication date |
---|---|
WO2000056403A1 (fr) | 2000-09-28 |
AU3760300A (en) | 2000-10-09 |
EP1175246A4 (fr) | 2004-12-15 |
EP1175246A1 (fr) | 2002-01-30 |
CA2368187A1 (fr) | 2000-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2003511347A (ja) | III型内皮細胞一酸化窒素合成酵素のHMG−CoA還元酵素阻害物質による上方制御 | |
US6147109A (en) | Upregulation of Type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors | |
US6180597B1 (en) | Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors | |
WO2000003746A2 (fr) | Remise a niveau de la synthase dl'oxyde nitrique des cellules endotheliales de type iii par des agents venant disloquer l'organisation cytosquelettique de l'actine | |
CA2358400C (fr) | Procedes de traitement d'etats associes a l'accumulation d'un excedent de matrice extracellulaire | |
US6696480B2 (en) | Upregulation of type III endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization | |
US10195204B2 (en) | Methods of treating hemoglobinopathies | |
EP1809742B1 (fr) | Methodes de traitement des etats associes a l'accumulation excessive de matrice extracellulaire | |
EP1014980A1 (fr) | Utilisation de nitroxydes dans le traitement de l'hypertension essentielle | |
JPH09500366A (ja) | 固形腫瘍及び他の疾患の治療のための薬剤の治療効果を改良する方法 | |
WO2009002533A1 (fr) | Thérapies d'affection abdominale inflammatoire | |
WO2006041763A1 (fr) | Inhibiteurs de renine pour le traitement de maladies induites par transplantation | |
JP2020520386A (ja) | 急性虚血性脳卒中の処置のための方法及び医薬組成物 | |
US20050038102A1 (en) | Upregulation of type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors | |
TW200920354A (en) | Association between an anti-atherothrombotic compound and an angiotensin-converting enzyme inhibitor | |
EP1721608A2 (fr) | Régulation positive de l'oxyde nitrique synthase de cellules endotheliales de type III par des inhibiteurs de la HMG-CoA reductase | |
AU2012200392B2 (en) | Methods for treating conditions associated with the accumulation of excess extracellular matrix | |
Mitch | Cardiovascular | |
AU2008200019B2 (en) | Methods for treating conditions associated with the accumulation of excess extracellular matrix | |
VM et al. | 12 NITRIC OXIDE MODULATES THE NEUROGENIC CONTROL OF BLOOD | |
Fraune et al. | Articles in PresS. Am J Physiol Renal Physiol (July 11, 2012). doi: 10.1152/ajprenal. 00672.2011 |